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Antitumoral effect of maintained 
neutrophilia induced by rhG-CSF 
in a murine model of pancreatic 
cancer
A. Brú1, R. Bosch2,3, M. V. Céspedes4,5, s. Carmona-Güedes4,5, e. Pascual3, I. Brú6 & 
J. C. souto3,7
Although the protumoral functions of polymorphonuclear neutrophils are well known, some now-
forgotten studies report antitumoral roles for these cells. The present work examines the antitumoral 
effect of maintained neutrophilia induced via the injection of recombinant human granulocyte 
colony stimulating factor (rhG-CSF, 100 μg/kg/day) in a Panc-1 subcutaneous xenograft murine 
model of pancreatic cancer. This treatment was compared with gemcitabine administration (120 mg/
kg every two days) and a saline control (n = 6–7 mice per group). Compared to the controls, both 
the rhG-CSF- and gemcitabine-treated mice showed significantly suppressed tumor growth by day 
4 (p < 0.001 and p = 0.013 respectively). From a mean starting volume of 106.9 ± 3.1 mm3 for all 
treatment groups, the final mean tumor volumes reached were 282.0 ± 30.7 mm3 for the rhG-CSF-
treated mice, 202.6 ± 18.1 mm3 for the gemcitabine-treated mice and 519.4 ± 62.9 mm3 for the control 
mice (p < 0.004 and p < 0.01, respectively, vs. control). The rhG-CSF-treated tumors showed higher 
percentage necrosis than those treated with gemcitabine (37.4 ± 4.6 vs. 7.5 ± 3.0; p < 0.001). This is 
the first report of a clear anti-tumoral effect of rhG-CSF when used in monotherapy against pancreatic 
cancer. Since rhG-CSF administration is known to be associated with very few adverse events, it may 
offer an attractive alternative in the clinical treatment of pancreatic cancer.
Pancreatic adenocarcinoma is an aggressive form of cancer1 that responds poorly to treatment. Most patients are 
diagnosed at an advanced stage, when over 50% already have metastases2,3. This cancer occupies fourth position 
in terms of overall mortality and first position in terms of mortality at 5 years (95%). Although numerous strat-
egies have been designed to improve the effectiveness of current treatments, the results have not been greatly 
encouraging, with median overall survival ranging from 5 to 11 months3. Finding a successful treatment for this 
condition is one of the greatest challenges in oncology.
In recent years, immunological therapies based on the adaptive immune response have generated much inter-
est as a means of fighting cancer. Chronic inflammation is commonly seen as a negative prognostic factor4, but 
there is growing evidence that acute inflammatory responses, involving mostly polymorphonuclear neutrophils 
(PMNs) and macrophages, help prevent the establishment and development of tumors5. Certainly, there is a qual-
itative difference between chronic and acute inflammation6. The former might be regarded as pro-tumoral given 
the accompanying degradation of the extracellular matrix around the tumor, which could allow for greater tumor 
growth and might also prevent tumor-seeking drugs from reaching their target. In maintained acute inflamma-
tion, however, the encapsulation of the tumor by neutrophils appears to have an antitumoral effect4,6,7. Indeed, 
a number of studies have shown that the critical factor affecting tumor growth is not the nutrient supply but the 
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availability of space into which the tumor can grow8; when a tumor is encapsulated by neutrophils, the necessary 
space is already occupied by these immune system cells.
Numerous studies4 have shown that the administration of recombinant human granulocyte colony stimu-
lating factor (rhG-CSF), which increases the number of circulating PMNs, has an antitumoral effect, probably 
via the above-mentioned mechanism. In humans, G-CSF is produced by many types of cell, including T cells, 
macrophages, endothelial cells and fibroblasts, upon receipt of the necessary stimulus. It then acts as a paracrine 
molecule that recruits neutrophils, monocytes and lymphocytes from the bloodstream to sites where they are 
needed. The aim of the present work was to examine the antitumoral effect of maintained neutrophilia induced 
by the administration of rhG-CSF in a xenograft murine model of pancreatic adenocarcinoma.
Results
rhG-CSF suppresses tumor growth in a xenograft model of pancreatic adenocarcinoma. A 
xenograft model of pancreatic adenocarcinoma using Panc-1 cells was generated in athymic mice to test and 
compare the antitumoral effect of rhG-CSF and gemcitabine.
To monitor the effects of these different treatments on blood cell counts, weekly blood samples were taken. 
At days 13 and 20, the granulocyte counts of the rhG-CSF-treated mice were three times those of the control and 
gemcitabine-treated groups (Fig. 1A). Neither monocyte nor lymphocyte counts were affected by rhG-CSF treat-
ment but were reduced with the gemcitabine treatment (data not shown).
The antitumoral response of the tested agents was determined by measuring the change in tumor volume 
over time. Both the rhG-CSF and gemcitabine treatments led to significant tumor growth suppression by day 4 
compared to controls (p < 0.001 and p = 0.013 respectively) (Fig. 1B); this size reduction was maintained until 
the end of the experiment (day 22) when the mice were killed. From a mean starting volume of 106.9 ± 3.1 mm3 
for all treatment groups, the final mean tumor volumes reached were 519.4 ± 62.9 mm3 for the control mice, 
282.0 ± 30.7 mm3 for the rhG-CSF-treated mice, and 202.6 ± 18.1 mm3 for the gemcitabine-treated mice 
(p = 0.004 and p < 0.001, respectively, vs. control), and p = 0.046 between the therapeutic treatments (Fig. 1C).
To assess the in vivo effects of the rhG-CSF and gemcitabine treatments, mouse body weight and behavior 
were monitored daily. The rhG-CSF treatment was associated with no increase in mortality, weight loss, signs of 
suffering, or macroscopic abnormalities suggestive of toxicity. However, the gemcitabine-treated animals showed 
cachexia and fatigue associated with a slight reduction in body weight by day 5; this lasted until the end of the 
experiment (Fig. 1D).
At necropsy, the final tumor weights in the rhG-CSF and gemcitabine-treated mice were significantly lower 
than in the controls (0.143 ± 0.029 g and 0.129 ± 0.018 g respectively vs. 0.316 ± 0.017 g [p = 0.005 and p = 0.002 
respectively; no significant difference) (Fig. 1E). No difference in final tumor weight was seen between the 
rhG-CSF- and gemcitabine-treated mice (p = 0.936).
In order to check that the rhG-CSF antitumor effect was not dependent on the cell line, the same schedule 
and dosage was administered in another xenograft model of pancreatic adenocarcinoma obtained by injection of 
MiaPaca cells in athymic mice. A significant reduction of tumor growth without any sign of toxicity was observed 
(Fig. 1 of Supplementary Information). The use of athymic/immunodeficient mice helped to claim that the innate 
immune response was the unique responsible for the rhG-CSF antitumor effect and eliminated the possibility 
that this antitumor effect could be guided by T lymphocytes. However, the antitumoral effect of rhG-CSF was also 
tested in a syngeneic lymphoma model using immunocompetent mice and similar results were obtained (Fig. 2 
of Supplementary Information).
rhG-CSF induced more intratumoral necrosis than did gemcitabine. Tumors treated with rhG-CSF 
showed higher percentages of necrosis than those treated with gemcitabine (37.4 ± 4.6% vs. 7.5 ± 3.0%; p < 0.001) 
(Fig. 2A). However, despite being significantly smaller in volume than the control tumors (as shown in Fig. 1B,C), 
those of the rhG-CSF-treated mice showed no significant differences to the latter with respect to the percentage 
of necrosis (37.4 ± 4.6% vs. 51.0 ± 9.9, respectively; p = 0.216) (Fig. 2B).
The spatial distribution of necrosis differed between rhG-CSF and gemcitabine-treated tum-
ors. The tumors of the control and rhG-CSF-treated mice showed more compact necrosis in their innermost 
region than seen for the gemcitabine-treated mice, in which the pattern of necrosis was more disperse and closer 
to the edge of the tumor. Using fractal dimension analysis to characterize the spatial distribution of this necro-
sis (Fig. 3A), the control and rhG-CSF-treated tumors were shown to have a similar necrotic pattern (mean 
df ± SEM: 1.75 ± 0.1 vs 1.78 ± 3 × 10−3, p = 0.701). However, these df values differed from that recorded for the 
tumors of the gemcitabine-treated mice (1.52 ± 0.1; p = 0.115 and p = 0.103 respectively) (Fig. 3B).
Proliferation was confined to the external part of the tumors in all treatments. The distribution 
of the proliferatively active cells was examined in three tumor regions (Fig. 4A). In the most external region, the 
proliferation rate exceeded 40% for all treatments. In the intermediate region, the proliferation rate was around 
30%, with no significant differences between treatments. In the most internal region, proliferative activity was at 
its lowest for all treatments, with no significant differences between treatments (Fig. 4B).
Discussion
The present results show that the daily administration of rhG-CSF suppresses tumor growth to an extent compa-
rable to that caused by gemcitabine in a xenograft model of pancreatic carcinoma.
To our knowledge, this is the first study to report the antitumoral effect of neutrophilia induced by rhG-CSF 
alone in a murine model of pancreatic cancer. Previously, however, Tamamori et al.9 reported a monoclonal anti-
body to have a stronger antitumoral effect when simultaneously administered with human rhG-CSF. In addition, 
neutrophils have been described as responsible for the antitumoral activity seen upon the inoculation of tumors 
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with bacterial lysates10 or live bacteria11, and for the suppression of tumor growth and metastasis associated with 
MUC5AC gene knockdown12 in murine pancreatic models. Moreover, rhG-CSF has been reported to have an 
antitumoral effect both alone and in association with other therapies in animal models of other types of cancer, 
and in all cases this effect has been clearly linked to an increased number of circulating and/or tumor-infiltrating 
PMNs. For example, the administration of rhG-CSF alone inhibited the formation of metastases in murine 
melanoma, lung cancer and lymphoma models13. rhG-CSF treatment combined with total body hyperthermia 
achieved an antitumoral effect greater than that seen with either treatment alone in a rat hepatoma model14. 
rhG-CSF plus the monoclonal anti-CD52 antibody (Alemtuzumab) increased survival from 60% to 100% at 12 
weeks in a mouse lymphoma model15. In an animal model of Ehrlich tumor, rhG-CSF treatment induced strong 
tumor necrosis and even eliminated some tumors6. Increasing the number of circulating PMNs is also reported 
to boost the efficacy of photodynamic therapy in a rhabdomyosarcoma model7, and the importance of increasing 
the number of circulating PMNs has been well demonstrated when seeking the elimination of melanoma and 
Walker 256 carcinoma in rats16,17.
Figure 1. In vivo antitumoral activity of rhG-CSF in an xenograft model of pancreatic adenocarcinoma. (A) 
Increase in granulocyte cell count (GRA) induced by rhG-CSF. (B) Tumor volume plotted against time for the 
different treatments. Error bars represent SEM. (C) Final tumor volumes for the different treatment groups (D). 
Mean daily tumor weight for each group plotted against days of treatment. (E) Final tumor weights. Error bars 
represent SEM. All differences were assessed using the Mann-Whitney U test.
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Evidence of the antitumoral activity of PMNs has also been gathered in humans. The intratumoral adminis-
tration of bacillus Calmette–Guérin (BCG) in human bladder cancer is one of the best examples of the potential 
of immunotherapy: high numbers of circulating PMNs correlated with a reduced recurrence of BCG-treated 
bladder tumors18,19. In a randomized, double-blind, placebo-controlled trial of head and neck squamous cell car-
cinoma, rhG-CSF treatment increased 5-year survival from 47% (placebo group) to 84%20. Importantly, rhG-CSF 
treatment was reported to cure a patient with terminal hepatocarcinoma21 - perhaps one of the most impor-
tant pieces of clinical evidence gathered to date on the positive antitumoral effect of intense and maintained 
neutrophilia.
The present work shows that daily administration of rhG-CSF alone induces a significant increase in the 
number of neutrophils, which is associated with a reduction in tumor volume in a murine model of pancreatic 
cancer. This reduction was not as great as that achieved with the gemcitabine treatment. However, it is important 
to remember that tumor volume was monitored using calipers. Thus, the volume measurements for the rhG-CSF 
treated mice might include both the tumor volume and the possible peritumoral inflammation obtained by the 
induction of neutrophilia; this could have led to overestimation of the true tumor volumes. Indeed, when final 
tumor weights were compared, the differences between the gemcitabine and rhG-CSF treatments were almost 
imperceptible. Moreover, intratumoral necrosis was more extensive in rhG-CSF- than in gemcitabine-treated 
tumors, suggesting that a longer treatment might achieve tumor regression.
Fractal dimension analysis showed the pattern of necrosis in the rhG-CSF-treated tumors to be different from 
that recorded for the gemcitabine-treated tumors. The pattern for the former tumors was largely localized to the 
internal part of the tumor, whereas that for the latter tumors was more disperse and external. This is probably 
because gemcitabine penetrates the tumor, killing it from the inside, while rhG-CSF causes encapsulating neu-
trophilia which exerts its killing effect from the outside. Indeed, the necrotic pattern for the rhG-CSF-treated 
tumors, and their distribution of proliferating cells, are fully compatible with the theory of universal dynamics of 
tumor growth described by Brú et al.8. In that study, it was shown that the main mechanism of tumor growth is 
Figure 2. Necrosis induced by the gemcitabine and rhG-CSF treatments. (A) H&E staining of three 
representative tumors from Panc1 xenograft mice treated with saline (control), gemcitabine, or rhG-CSF. 
Images are shown at their original magnification (x40). Necrotic areas are shown with black arrows. (B) 
Percentage necrosis. Error bars represent SEM. Differences were examined using the Student t test.
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the division and surface movement or ‘diffusion’ of cells at the tumor border, where space is still available. Indeed, 
space is constantly being made available here via the lytic processes unleashed against the host tissue22. Inside the 
tumor, however, where no space is available, the cells become quiescent and eventually necrotic. Based on the 
results of previous work6,8, it was hypothesized that, when rhG-CSF is administered, the resulting intense peritu-
moral neutrophilia exerts a “pressure effect” that impedes tumor cell diffusion at the tumor surface, impairing the 
proliferation of tumor cells and causing the cessation of tumor growth. This is accompanied by the eventual inter-
nal necrosis of the tumor. Indeed, and in agreement with the results of previous findings8,23, the present results 
revealed proliferative activity to be much greater in the external zone of the tumors (Fig. 4).
It should be noted that the neutrophilia induced by the rhG-CSF treatment was associated with no sign of tox-
icity, while the gemcitabine-treated mice showed cachexia and fatigue associated with a slight loss of body weight. 
Unlike the severe adverse effects associated with the use of gemcitabine in humans24, rhG-CSF is a very safe drug 
with minimal side effects25. In addition, sustained neutrophilia seems to be a well-tolerated treatment20, although 
this requires formal clinical confirmation. Nonetheless, the present results suggest that rhG-CSF treatment for 
pancreatic cancer in humans could be effective and safe.
In conclusion, this is the first study to report the antitumoral effect of rhG-CSF alone in a murine model of 
pancreatic cancer. This treatment increased the granulocyte count without inducing any sign of toxicity. Although 
a modest study, the results are promising enough to suggest that enhancing the innate immune response via 
rhG-CSF treatment might be beneficial against pancreatic cancer, and perhaps other tumors.
Materials and Methods
Cell line and compounds. Human pancreatic adenocarcinoma Panc-1 cells (CRL-149, ATCC, Virginia, 
USA) were cultured in DMEM supplemented with 10% fetal bovine serum, 1% glutamine, 100 units/mL peni-
cillin/streptomycin (Life Technologies, Carlsbad, CA, USA), and incubated at 37 °C in a humidified atmosphere 
containing 5% CO2. Gemcitabine (38 mg/ml) (Hospira, Maidenhead UK) and rhG-CSF (Neupogen) (Amgen, 
Thousand Oaks, CA, USA) were obtained from the Pharmacy Department of Hospital de la Santa Creu i Sant Pau.
Animals. Female athymic Swiss nu/nu mice (Harlan Laboratories Inc., Italy) aged 4–6 weeks weigh-
ing 18–20 g, were housed in individually ventilated cages at 21–23 °C and 40–60% humidity, and under a 12 h 
Figure 3. Distribution pattern of necrosis induced by gemcitabine and rhG-CSF. H&E staining of three 
representative tumors from Panc1 xenograft mice treated with saline (control), gemcitabine or rhG-CSF, plus 
images showing the necrotic area (shown in black). The fractal dimensions (df) of the necrotic regions were 
determined for each tumor. Results are expressed as Mean ± SEM. (B) Differences in df between groups. Error 
bars represent SEM. Statistical analysis was performed using the Student t-test.
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light-dark cycle. All mice were allowed free-access to an irradiated diet and sterilized water. Animal procedures 
were reviewed and approved by the Hospital Sant Pau Animal Ethics Committee and the regional Institutional 
Animal Care and Use Committee.
In vivo experiments. Panc1 cells were injected subcutaneously (20 × 106 cells per flank) into two mice to 
produce donor tumors. Once grown to 100–120 mm3, these donor tumors were cut into fragments of 2–3 mm3 
and implanted subcutaneously into host mice (as previously described26) that had been randomized into three 
groups: (1) rhG-CSF treatment (n = 7), involving daily administration of subcutaneous rhG-SCF (100 μg/
kg in 0.5 mL mm3 of saline); (2) intraperitoneal gemcitabine treatment (n = 7) (120 mg/kg every two days in 
0.5 mL mm3 of saline); and (3) control group (n = 6), involving the subcutaneous administration of 0.5 mL mm3 of 
saline every day. No differences were seen in the initial mean tumor dimensions or weight, or mouse body weight, 
for each group. Body weight and tumor volumes were recorded twice per week. Tumors were measured using a 
caliper and volumes estimated according to the formula V = (a.b2)/2, (a: length or longest diameter; b: width or 
shortest diameter). Measurement began on the first day of treatment (day 0) and finished on day 22 (when the 
first tumor in the control group reached 1.5 cm in diameter), at which time all mice were sacrificed. All tumors 
were then removed, fixed in formalin, and paraffin-embedded for histopathological and immunohistochemical 
studies.
Blood collection and hematological measurements. A weekly 150 μl blood simple was collected in 
EDTA tubes (Aquisel K3E, Barcelona, Spain) from three mice per group via intramandibular plexus puncture. 
Hematological analyses were performed using an automated hematology analyzer (Abacus junior vet, Practice 
CVM, Navarra, Spain) according to the manufacturer’s specifications and using mouse-specific algorithms 
(Abacus Software, v.1.21). The variables determined included leukocyte (WBC), lymphocyte (LYM), granulocyte 
(GRA) and monocyte (MYD) counts.
Quantification of tumor necrosis and proliferation rates. Paraffin-embedded tissue sections of Panc1 
tumors were stained with hematoxylin and eosin (H&E) or Ki67 (DAKO, Carpinteria, CA, USA), a molecule that 
highlights proliferating cells. Immunohistochemical reactions were performed in a DAKO Autostainer Link48 
following the manufacturer’s instructions. All slides were viewed using an Olympus BX15 microscope. Images 
were acquired using an Olympus DP72 digital camera and processed with Olympus Cell D Imaging 3.3 software 
(Olympus Corporation, Tokyo, Japan); the final resolution was 1.3 microns/pixel.
Figure 4. Distribution of active cells inside tumors treated with gemcitabine or rhG-CSF. (A) Outer, 
intermediate and inner regions of the tumor, representing 20% 30% and 50% of the tumor cross-sectional area 
respectively. (B) Percentage of Ki67- positive cells in each tumor region after treatment with gemcitabine or 
rhG-CSF. Results are expressed as mean percentages ± SEM.
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Percentage intratumoral necrosis was determined by image processing using verified in-house software8. To 
characterize the spatial distribution of necrosis inside the tumors, the fractal dimension (df) was calculated using 
the box counting method, using the same in-house software.
The proliferation rate - determined as the percentage of Ki67-positive cells (brown nuclear staining) over the 
total number of tumor cells - was calculated for three tumor regions: an external region accounting for 20% of the 
total cross sectional area, an intermediate region accounting for 30%, and an inner region accounting for 50%8.
Statistical analysis. Data were expressed as means ± standard errors. Data sets consisting of more than two 
groups were analyzed by one-way ANOVA. Differences between means were assessed using the Student t test or 
Mann Whitney U test as required. All analyses were performed using GraphPad Prism v5.02 (GraphPad Software 
Inc.).
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